Vocinti Dosage/Direction for Use

Gastric ulcer, duodenal ulcer: Usually, for adults, a daily oral dose of 20 mg of vonoprazan is administered once a day. For the treatment of gastric ulcer, the usual administration should be limited up to 8 weeks, and for duodenal ulcer, up to 6 weeks.
Reflux esophagitis: Usually, for adults, a daily oral dose of 20 mg of vonoprazan is administered once a day. The usual administration should be limited up to 4 weeks. However, when the effect is insufficient, the drug may be administered up to 8 weeks. In addition, for the maintenance of healing of reflux esophagitis to prevent recurrence or relapse of the condition, a daily oral dose of 10 mg is administered once a day until 24 weeks.
Prevention of recurrence of gastric ulcer or duodenal ulcer during low-dose aspirin administration: Usually, for adults, a daily oral dose of 10 mg of vonoprazan is administered once a day.
Prevention of recurrence of gastric ulcer or duodenal ulcer during NSAIDs administration: Usually, for adults, a daily oral dose of 10 mg of vonoprazan is administered once a day.
Adjunct to Helicobacter pylori eradication: Usually, for adults, the following 3 drugs are orally administered at the same time twice daily for 7 days: 20 mg/dose of vonoprazan, amoxicillin hydrate, and clarithromycin.
When Helicobacter pylori eradication treatment with 3 drugs consist of a proton pump inhibitor, amoxicillin hydrate, and clarithromycin fails, alternative treatment with the following 3 drugs is given; usually, for adults, 20 mg/dose of vonoprazan, amoxicillin hydrate, and metronidazole are orally administered at the same time twice daily for 7 days. The doses of antibiotics should follow the latest National Consensus on Management of Dyspepsia & Helicobacter pylori infection recommendations for Helicobacter pylori infections.
Careful Administration: VOCINTI Tablets should be administered with care in the following patients:
(1) Patients with hepatic disorders [A delay in the metabolism and excretion of VOCINTI Tablets may occur, which may result in an increase in the concentration of vonoprazan in blood.]
(2) Patients with renal disorders [A delay in the excretion of VOCINTI Tablets may occur, which may result in an increase in the concentration of vonoprazan in blood.]
(3) Elderly patients.
Special Patient Populations: Elderly Patients: Since the physiological functions such as hepatic or renal function are decreased in elderly patients in general, vonoprazan should be carefully administered.
Pediatric Use: Vonoprazan has not been studied in patients under 18 years of age.
Impaired Renal Function: Vonoprazan should be administered with care in patients with renal disorders as a delay in the excretion of vonoprazan may occur, which may result in an increase in the concentration of vonoprazan in the blood.
Impaired Hepatic Function: Vonoprazan should be administered with care in patients with hepatic disorders as a delay in the metabolism and excretion of vonoprazan may occur, which may result in an increase in the concentration of vonoprazan in the blood.